Literature DB >> 15273130

Distribution of human immunodeficiency virus type 1 protease and reverse transcriptase mutation patterns in 4,183 persons undergoing genotypic resistance testing.

Soo-Yon Rhee1, Tommy Liu, Jaideep Ravela, Matthew J Gonzales, Robert W Shafer.   

Abstract

In a sample of 6,156 sequences from 4,183 persons, the top 30 patterns of protease inhibitor, nucleoside reverse transcriptase (RT) inhibitor, and nonnucleoside RT inhibitor mutations accounted for 55, 46, and 66%, respectively, of sequences with drug resistance mutations. Characterization of the phenotypic and clinical significance of these common patterns may lead to improved treatment recommendations for a large proportion of patients for whom antiretroviral therapy is failing.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15273130      PMCID: PMC478552          DOI: 10.1128/AAC.48.8.3122-3126.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  5 in total

1.  Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.

Authors:  P A Cane; A de Ruiter; P Rice; M Wiselka; R Fox; D Pillay
Journal:  J Clin Microbiol       Date:  2001-07       Impact factor: 5.948

2.  Protease and reverse transcriptase mutation patterns in HIV type 1 isolates from heavily treated persons: comparison of isolates from Northern California with isolates from other regions.

Authors:  Matthew J Gonzales; Ilana Belitskaya; Kathryn M Dupnik; Soo-Yon Rhee; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2003-10       Impact factor: 2.205

3.  A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.

Authors:  Bluma Brenner; Dan Turner; Maureen Oliveira; Daniela Moisi; Mervi Detorio; Mauricio Carobene; Richard G Marlink; Jonathan Schapiro; Michel Roger; Mark A Wainberg
Journal:  AIDS       Date:  2003-01-03       Impact factor: 4.177

4.  A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1.

Authors:  C J Petropoulos; N T Parkin; K L Limoli; Y S Lie; T Wrin; W Huang; H Tian; D Smith; G A Winslow; D J Capon; J M Whitcomb
Journal:  Antimicrob Agents Chemother       Date:  2000-04       Impact factor: 5.191

5.  Human immunodeficiency virus reverse transcriptase and protease sequence database.

Authors:  Soo-Yon Rhee; Matthew J Gonzales; Rami Kantor; Bradley J Betts; Jaideep Ravela; Robert W Shafer
Journal:  Nucleic Acids Res       Date:  2003-01-01       Impact factor: 16.971

  5 in total
  40 in total

1.  A novel nonnucleoside analogue that inhibits human immunodeficiency virus type 1 isolates resistant to current nonnucleoside reverse transcriptase inhibitors.

Authors:  Zhijun Zhang; Wen Xu; Yung-Hyo Koh; Jae Hoon Shim; Jean-Luc Girardet; Li-Tain Yeh; Robert K Hamatake; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

2.  Panel of prototypical infectious molecular HIV-1 clones containing multiple nucleoside reverse transcriptase inhibitor resistance mutations.

Authors:  Elizabeth Johnston; Kathryn M Dupnik; Matthew J Gonzales; Mark A Winters; Soo-Yon Rhee; Tomozumi Imamichi; Robert W Shafer
Journal:  AIDS       Date:  2005-04-29       Impact factor: 4.177

3.  N88D facilitates the co-occurrence of D30N and L90M and the development of multidrug resistance in HIV type 1 protease following nelfinavir treatment failure.

Authors:  Yumi Mitsuya; Mark A Winters; W Jeffrey Fessel; Soo-Yon Rhee; Leo Hurley; Michael Horberg; Celia A Schiffer; Andrew R Zolopa; Robert W Shafer
Journal:  AIDS Res Hum Retroviruses       Date:  2006-12       Impact factor: 2.205

4.  Potent new antiviral compound shows similar inhibition and structural interactions with drug resistant mutants and wild type HIV-1 protease.

Authors:  Yuan-Fang Wang; Yunfeng Tie; Peter I Boross; Jozsef Tozser; Arun K Ghosh; Robert W Harrison; Irene T Weber
Journal:  J Med Chem       Date:  2007-08-16       Impact factor: 7.446

Review 5.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART.

Authors:  Robert W Shafer; Jonathan M Schapiro
Journal:  AIDS Rev       Date:  2008 Apr-Jun       Impact factor: 2.500

6.  Novel nonnucleoside inhibitors that select nucleoside inhibitor resistance mutations in human immunodeficiency virus type 1 reverse transcriptase.

Authors:  Zhijun Zhang; Michelle Walker; Wen Xu; Jae Hoon Shim; Jean-Luc Girardet; Robert K Hamatake; Zhi Hong
Journal:  Antimicrob Agents Chemother       Date:  2006-08       Impact factor: 5.191

7.  Conformational Plasticity of the NNRTI-Binding Pocket in HIV-1 Reverse Transcriptase: A Fluorine Nuclear Magnetic Resonance Study.

Authors:  Naima G Sharaf; Rieko Ishima; Angela M Gronenborn
Journal:  Biochemistry       Date:  2016-07-11       Impact factor: 3.162

8.  A systems analysis of mutational effects in HIV-1 protease and reverse transcriptase.

Authors:  Trevor Hinkley; João Martins; Colombe Chappey; Mojgan Haddad; Eric Stawiski; Jeannette M Whitcomb; Christos J Petropoulos; Sebastian Bonhoeffer
Journal:  Nat Genet       Date:  2011-03-27       Impact factor: 38.330

9.  HIV-1 subtypes and drug resistance profiles in a cohort of heterosexual patients in Istanbul, Turkey.

Authors:  Muammer Osman Köksal; Hayati Beka; Nadine Lübke; Jens Verheyen; Haluk Eraksoy; Atahan Cagatay; Rolf Kaiser; Baki Akgül; Ali Agacfidan
Journal:  Med Microbiol Immunol       Date:  2015-04-28       Impact factor: 3.402

10.  Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update.

Authors:  Diane E Bennett; Ricardo J Camacho; Dan Otelea; Daniel R Kuritzkes; Hervé Fleury; Mark Kiuchi; Walid Heneine; Rami Kantor; Michael R Jordan; Jonathan M Schapiro; Anne-Mieke Vandamme; Paul Sandstrom; Charles A B Boucher; David van de Vijver; Soo-Yon Rhee; Tommy F Liu; Deenan Pillay; Robert W Shafer
Journal:  PLoS One       Date:  2009-03-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.